The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) rose by more than 11%. As of press release, it had risen 11.42% to HK$27.32, with a turnover of HK$334 million.

According to the news, recently, Zhaoyan Pharmaceutical released its 2026 semi-annual performance forecast. China Post Securities indicated that in the first half of 2026, the company expects to achieve operating income of about 669 million yuan to 739 million yuan (+0% to 10.5% year over year), and realized net profit of about 600 million yuan to 900 million yuan (+884.9% to 1377.4% year over year), and realized net profit of about 561 million yuan to 842 million yuan (+2334.2% to 3551.3% year over year).

China Post Securities believes that positive changes in the fair value of biological assets have become the core driving force behind Zhaoyan Pharmaceutical's performance explosion in the current period. Net profit from changes in the fair value of 2026H1's biological assets was about 703 million yuan to 777 million yuan, a significant increase from 88 million yuan in the same period in 2025. As a CRO company with its own breeding base for non-human primate experimental models, the population resource advantage not only guarantees the supply chain security of its own non-clinical evaluation business, but also directly translates into performance flexibility through fair value revaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.